The company said total revenue for Q3 2025 was $2,535 million, up 3% from $2,466 million a year earlier. GAAP diluted EPS was $3.17 and Non-GAAP diluted EPS was $4.81.

1. 01

   The company said total revenue for Q3 2025 was $2,535 million, up 3% from $2,466 million a year earlier. GAAP diluted EPS was $3.17 and Non-GAAP diluted EPS was $4.81.

2. 02

   Biogen said LEQEMBI global in-market sales for Q3 were approximately $121 million, up 82% year over year. It said SKYCLARYS global revenue was approximately $133 million, up 30%, and ZURZUVAE revenue was approximately $55 million.

3. 03

   Biogen Inc. said net cash flow from operations for Q3 2025 was approximately $1.3 billion, capital expenditures were approximately $46 million, and free cash flow (Non-GAAP) was approximately $1.2 billion. As of September 30, 2025, the company had cash and cash equivalents of approximately $4.0 billion, total debt of approximately $6.3 billion, and net debt of approximately $2.3 billion.

4. 04

   The company said it updated its full-year 2025 Non-GAAP diluted EPS guidance to $14.50 to $15.00, reflecting an improved business outlook of +$0.25 and an approximate $1.25 impact from business development transactions expected to close in Q4, compared with prior guidance of $15.50 to $16.00.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.